Aminoglutethimide

What is Aminoglutethimide?

Aminoglutethimide is a pharmaceutical compound that historically served as a critical agent in the treatment of certain hormone-dependent conditions, particularly cancers. Classified primarily as an aromatase inhibitor, it works by blocking the production of estrogens in the body. Beyond this, it also inhibits several enzymes involved in adrenal steroidogenesis, leading to a reduction in the synthesis of various adrenal hormones, including cortisol, aldosterone, and androgens.

First synthesized in the 1950s, Aminoglutethimide was initially introduced as an anticonvulsant. However, its significant side effect of adrenal suppression quickly led to its withdrawal from this use. Later, researchers discovered its potential as an endocrine-modulating agent, especially for conditions where the reduction of specific hormones could be therapeutically beneficial. This led to its repurposing for treating certain hormone-dependent cancers, marking a significant step in endocrine therapy.

How Does it Work?

The therapeutic efficacy of Aminoglutethimide stems from its unique dual mechanism of action, primarily impacting hormone synthesis:

• Aromatase Inhibition: One of its main actions is the non-selective inhibition of the aromatase enzyme (CYP19). This enzyme is responsible for the conversion of androgens (like androstenedione and testosterone) into estrogens (estrone and estradiol) in peripheral tissues (e.g., fat, muscle, liver) and, to a lesser extent, in the adrenal glands. By blocking aromatase, Aminoglutethimide effectively reduces circulating estrogen levels, which is crucial in treating estrogen-receptor-positive breast cancers that rely on estrogen for growth.
• Adrenal Steroid Synthesis Inhibition: Aminoglutethimide also inhibits several cytochrome P450 enzymes involved in the adrenal gland's steroid synthesis pathway. Specifically, it blocks cholesterol desmolase (CYP11A1), an enzyme essential for the conversion of cholesterol to pregnenolone, the rate-limiting step in adrenal steroid production. This broad inhibition leads to a reduction in the synthesis of glucocorticoids (like cortisol), mineralocorticoids (like aldosterone), and adrenal androgens. This effect is particularly relevant for conditions like Cushing's syndrome or adrenocortical carcinoma.

Due to its broad inhibition of adrenal steroid synthesis, patients receiving Aminoglutethimide often require concomitant corticosteroid replacement therapy (e.g., hydrocortisone) to prevent adrenal insufficiency.

Medical Uses

Aminoglutethimide has been used in various medical contexts, primarily leveraging its hormone-suppressing capabilities:

• Metastatic Breast Cancer: Its most prominent use has been in the treatment of advanced or metastatic breast cancer in postmenopausal women. By significantly reducing estrogen production, it could slow or halt the growth of estrogen-receptor-positive tumors that are sensitive to hormonal manipulation. It was often used as a second-line therapy after tamoxifen or as an alternative in tamoxifen-resistant cases.
• Adrenocortical Carcinoma: Given its ability to inhibit cortisol synthesis, Aminoglutethimide has been employed in the management of adrenocortical carcinoma, especially in cases where the tumor produces excessive amounts of steroids, leading to symptoms of Cushing's syndrome.
• Cushing's Syndrome: For patients with endogenous Cushing's syndrome, a condition characterized by excessive cortisol production, Aminoglutethimide can help to reduce cortisol levels, thereby alleviating symptoms associated with hypercortisolism. This use is particularly relevant when surgery is not an option or as an adjunct to other treatments.

While newer, more selective aromatase inhibitors (e.g., anastrozole, letrozole) have largely replaced Aminoglutethimide in breast cancer treatment due to better tolerability and selectivity, it remains historically significant and may still be considered in specific, refractory cases or for its unique adrenal suppressive properties.

Dosage

The dosage of Aminoglutethimide must be carefully individualized by a healthcare professional, considering the patient's condition, response to treatment, and potential side effects. It is administered orally, typically in divided doses throughout the day to maintain consistent drug levels.

For breast cancer, a common starting dose might be 250 mg daily, gradually increasing over several weeks to a maintenance dose of 250 mg four times a day (1000 mg/day). In cases of Cushing's syndrome or adrenocortical carcinoma, the dosage may vary depending on the degree of steroid suppression required and the patient's tolerance.

Crucially, due to its inhibition of cortisol synthesis, patients receiving Aminoglutethimide usually require concurrent corticosteroid replacement therapy, such as hydrocortisone, to prevent drug-induced adrenal insufficiency. This replacement therapy typically starts at the same time as Aminoglutethimide or shortly after, and its dosage also needs careful titration.

Side Effects

Aminoglutethimide is associated with a range of side effects, some of which are significant and necessitate careful monitoring:

• Neurological: Drowsiness, lethargy, dizziness, ataxia (impaired coordination), and headache are common, especially at the initiation of therapy. These often diminish with continued treatment.
• Gastrointestinal: Nausea, vomiting, and anorexia can occur.
• Dermatological: Skin rash, which can sometimes be severe, is a relatively common side effect. It usually appears within the first few weeks of treatment and may necessitate discontinuation if persistent or severe.
• Endocrine/Metabolic:
  • Adrenal Insufficiency: This is a major concern due to its mechanism of action, making corticosteroid replacement essential.
  • Hypothyroidism: Aminoglutethimide can interfere with thyroid hormone synthesis, potentially leading to hypothyroidism. Thyroid function tests are often monitored.
  • Fluid Retention: Edema can occur in some patients.
• Hematological: Less commonly, blood dyscrasias like leukopenia (low white blood cell count) or thrombocytopenia (low platelet count) have been reported.

Patients should be closely monitored for these side effects, and dosage adjustments or supportive therapies may be required.

Drug Interactions

Aminoglutethimide can interact with several other medications, altering their efficacy or increasing the risk of adverse effects:

• Corticosteroids: It significantly interacts with corticosteroids. While hydrocortisone is co-administered to prevent adrenal insufficiency, Aminoglutethimide can increase the metabolism of dexamethasone, reducing its effectiveness.
• Anticoagulants: Aminoglutethimide can induce hepatic enzymes, potentially increasing the metabolism of oral anticoagulants like warfarin, leading to a reduced anticoagulant effect. Close monitoring of INR and dosage adjustments may be necessary.
• Theophylline and Digoxin: Similar to anticoagulants, Aminoglutethimide can accelerate the metabolism of drugs like theophylline (used for respiratory conditions) and digoxin (for heart conditions), potentially leading to subtherapeutic levels.
• Other CNS Depressants: Concurrent use with alcohol or other central nervous system depressants can exacerbate drowsiness and lethargy.
• Thyroid Hormones: As it can induce hypothyroidism, it may alter the requirements for thyroid hormone replacement therapy.

Patients should inform their doctor about all medications, supplements, and herbal products they are taking to avoid potential interactions.

FAQ

Is Aminoglutethimide still commonly used today?

While still available, Aminoglutethimide is less commonly used today, especially for breast cancer, having been largely superseded by newer, more selective aromatase inhibitors with better safety profiles. However, it may still be considered in specific clinical scenarios, such as certain cases of adrenocortical carcinoma or Cushing's syndrome, or in patients who have failed other therapies.

What type of cancer does Aminoglutethimide treat?

Historically, Aminoglutethimide was primarily used to treat advanced or metastatic estrogen-receptor-positive breast cancer in postmenopausal women. It has also been used in the management of adrenocortical carcinoma.

Why is hydrocortisone given with Aminoglutethimide?

Hydrocortisone (or another corticosteroid) is typically given concurrently with Aminoglutethimide to prevent drug-induced adrenal insufficiency. Aminoglutethimide inhibits the synthesis of cortisol by the adrenal glands, which, if not compensated, can lead to a life-threatening lack of essential adrenal hormones.

How long does it take for Aminoglutethimide to work?

The time to observe therapeutic effects can vary depending on the condition being treated. Reductions in estrogen or cortisol levels can occur relatively quickly after initiating treatment. Clinical responses in cancer treatment, however, may take several weeks or months to become evident.

Products containing Aminoglutethimide are available through trusted online pharmacies. You can browse Aminoglutethimide-based medications at ShipperVIP or Medicenter.

Summary

Aminoglutethimide is a multifaceted pharmaceutical agent known for its dual ability to inhibit aromatase and suppress adrenal steroidogenesis. While its role in breast cancer treatment has largely been taken over by newer, more selective drugs, it remains a significant historical compound in endocrine therapy. Its unique mechanism of action made it valuable for managing hormone-dependent breast cancers, adrenocortical carcinoma, and Cushing's syndrome. Due to its broad impact on hormone synthesis, careful dosing and vigilant management of side effects, particularly adrenal insufficiency requiring corticosteroid replacement, are paramount. Patients considering or undergoing treatment with Aminoglutethimide must do so under strict medical supervision to maximize benefits and mitigate risks.